November 22nd, 2009

Podcast 66: Niacin versus ezetimibe in the face of high cardiovascular risk — a conversation with the ARBITER 6-HALTS trialist Allen Taylor

(3 votes, average: 4.00 out of 5)

One of the more intriguing pieces of research presented at the American Heart Association this week (and simultaneously released online in the New England Journal of Medicine) shows that extended-release niacin outperforms ezetimibe in high-risk patients. We talk with Dr. Allen J. Taylor, the study’s first author.

Contact us at 1-617-440-4374 or write jelia@jwatch.org.

This edition’s links:

Interview Link:

News Links:

Comments are closed.

Clinical Conversations

About the Podcast

To subscribe:

Comments, suggestions, and story ideas welcome. Learn more about Clinical Conversations.